Evidence map›Paper›PMID 25336613›Full record

ArticleScience signaling2014

RhoA signaling in cardiomyocytes protects against stress-induced heart failure but facilitates cardiac fibrosis.

Jessica Lauriol, Kimberly Keith, Fabrice Jaffré, Anthony Couvillon, Abdel Saci, Sanjeewa A Goonasekera, Jason R McCarthy, Chase W Kessinger, Jianxun Wang, Qingen Ke and 4 more

Open access · greenAbstract read
In one paragraph

Article in Science signaling, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 1 synthesis or guideline pooled it, 85 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Dock10 Regulates Cardiac Function under Neurohormonal Stress.International journal of molecular sciences · 2022
    Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Jessica LauriolDepartment of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA.
Kimberly KeithDepartment of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA.
Fabrice JaffréDepartment of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA.
Anthony CouvillonDepartment of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA.
Abdel SaciDepartment of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA.
Sanjeewa A GoonasekeraDepartment of Pediatrics, University of Cincinnati, Cincinnati Children's Hospital Medical Center, Howard Hughes Medical Institute, Cincinnati, OH 45229, USA.
Jason R McCarthyCenter for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Chase W KessingerCardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Jianxun WangDepartment of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA.
Qingen KeDepartment of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA.
Peter M KangDepartment of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA.
Jeffery D MolkentinDepartment of Pediatrics, University of Cincinnati, Cincinnati Children's Hospital Medical Center, Howard Hughes Medical Institute, Cincinnati, OH 45229, USA.
Christopher CarpenterDepartment of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA.
Maria I KontaridisDepartment of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA. Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA. mkontari@bidmc.harvard.edu.
Beth Israel Deaconess Medical Center · USHarvard University · USCincinnati Children's Hospital Medical Center · USHoward Hughes Medical Institute · US

Funding

Harvard Clinical and Translational Science CenterUL1TR001102 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$106.2M
The Role of RhoA in the Molecular Pathogenesis of Heart DiseaseR01HL102368 · NHLBI · MASONIC MEDICAL RESEARCH LABORATORY, INC · PI KONTARIDIS, MARIA I · 2010 to 2021
$5.1M
Elucidating the Phosphatase-Independent Roles of PTPN11 in the HeartR01HL114775 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KONTARIDIS, MARIA I · 2013 to 2016
$1.7M
NCATS NIH HHS UL1 TR001102NHLBI NIH HHS R01 HL102368NHLBI NIH HHS R01-HL102368NHLBI NIH HHS R01 HL114775NHLBI NIH HHS R01-HL114775
6 · The paper itself

Abstract

The Ras-related guanosine triphosphatase RhoA mediates pathological cardiac hypertrophy, but also promotes cell survival and is cardioprotective after ischemia/reperfusion injury. To understand how RhoA mediates these opposing roles in the myocardium, we generated mice with a cardiomyocyte-specific deletion of RhoA. Under normal conditions, the hearts from these mice showed functional, structural, and growth parameters similar to control mice. Additionally, the hearts of the cardiomyocyte-specific, RhoA-deficient mice subjected to transverse aortic constriction (TAC)-a procedure that induces pressure overload and, if prolonged, heart failure-exhibited a similar amount of hypertrophy as those of the wild-type mice subjected to TAC. Thus, neither normal cardiac homeostasis nor the initiation of compensatory hypertrophy required RhoA in cardiomyocytes. However, in response to chronic TAC, hearts from mice with cardiomyocyte-specific deletion of RhoA showed greater dilation, with thinner ventricular walls and larger chamber dimensions, and more impaired contractile function than those from control mice subjected to chronic TAC. These effects were associated with aberrant calcium signaling, as well as decreased activity of extracellular signal-regulated kinases 1 and 2 (ERK1/2) and AKT. In addition, hearts from mice with cardiomyocyte-specific RhoA deficiency also showed less fibrosis in response to chronic TAC, with decreased transcriptional activation of genes involved in fibrosis, including myocardin response transcription factor (MRTF) and serum response factor (SRF), suggesting that the fibrotic response to stress in the heart depends on cardiomyocyte-specific RhoA signaling. Our data indicated that RhoA regulates multiple pathways in cardiomyocytes, mediating both cardioprotective (hypertrophy without dilation) and cardio-deleterious effects (fibrosis).

Indexed as

MAP Kinase Signaling SystemStress, PhysiologicalAnimalsAortic DiseasesEndomyocardial FibrosisHeart FailureMiceMice, TransgenicMitogen-Activated Protein Kinase 3Myocytes, CardiacProto-Oncogene Proteins c-aktrhoA GTP-Binding Proteinrho GTP-Binding ProteinsMitogen-Activated Protein Kinase 3Proto-Oncogene Proteins c-aktrhoA GTP-Binding ProteinRhoA protein, mouserho GTP-Binding Proteins

Identifiers

PMID25336613
PMCPMC4300109
OpenAlexW1991092434

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.